Xenon Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Xenon Pharmaceuticals Inc XENE.OQ reported a quarterly adjusted loss of 83 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -62 cents. The mean expectation of seventeen analysts for the quarter was for a loss of 91 cents per share. Wall Street expected results to range from -100 cents to -79 cents per share.

• Revenue was $7.50 million​; analysts expected $1.11 million.

• Xenon Pharmaceuticals Inc's reported EPS for the quarter was a loss of 83 cents​.

• The company reported a quarterly loss of $65.05 million.

• Xenon Pharmaceuticals Inc shares had risen by 4.4% this quarter and lost 10.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 5.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Xenon Pharmaceuticals Inc is $58.00

This summary was machine generated from LSEG data May 12 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)